Monthly
cost of providing key drugs could be $1-2 per person: experts
Send a link to a friend
[November 08, 2016]
By Magdalena Mis
LONDON (Thomson Reuters Foundation) -
Essential medicines could be provided for as little as $1-$2 a month per
person in developing countries, experts said on Monday as they called on
governments to boost efforts to ensure everyone can access basic
healthcare.
|
Although global spending on medicines is about eight times this
amount, one in five countries spends less than $1 per month per
person, according to the first analysis of the cost of providing key
drugs by The Lancet Commission on Essential Medicines.
The commission, comprising 21 international experts, said lack of
access to affordable, quality medicines was threatening progress
towards universal health coverage, one of the targets under the new
global development goals adopted by world leaders at a U.N. summit
last year.
The list of essential medicines contains 201 drugs needed for a
basic healthcare system and includes HIV, malaria and cancer drugs,
vaccines and contraceptives. The list is updated by the World Health
Organization every two years.
"The affordability of essential medicines is a core challenge and is
a challenge to ... our ability to deliver universal health
coverage," commission co-chair and pharmacist Andy Gray told a
telephone media briefing.
Gray, a senior lecturer at South Africa's University of KwaZulu-Natal,
called for additional financing to meet basic healthcare needs and
said low-income countries that struggle to meet them should receive
support from the international community.
Based on disease prevalence, consumption of medicines and the price
of drugs, the commission estimated the cost of providing essential
medicines to the populations of low- and middle-income countries to
be between $77 billion and $152 billion a year.
It said 41 countries were spending less than $1 per person per month
on medicines while global spending on medicines in 2017 was
predicted to be $1.2 trillion.
[to top of second column] |
The experts said "massive inequities and inefficiencies" in
financing and governance were restricting access to drugs for many
people.
They said persistent problems with the quality and safety of
medicines in many low- and middle-income countries must also be
addressed with better regulation.
For example, over 120,000 children in sub-Saharan Africa are
estimated to have died in 2013 because of substandard anti-malarial
medicines, the commission said.
The experts also called for urgent reforms in the way essential
drugs are developed and patented to improve affordability and
access.
(Editing by Emma Batha.; Please credit the Thomson Reuters
Foundation, the charitable arm of Thomson Reuters, which covers
humanitarian news, women's rights, trafficking, corruption and
climate change. Visit news.trust.org to see more stories.)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|